Solid Biosciences (SLDB) Total Liabilities (2017 - 2026)

Solid Biosciences has disclosed Total Liabilities across 10 years of filings, most recently posting $48.8 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $48.8 million, down 1.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.8 million (down 1.38% YoY), and the FY2025 annual result was $52.5 million, up 2.17% from the prior year.
• Total Liabilities came in at $48.8 million for Q1 2026 at Solid Biosciences, down from $52.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $56.0 million in Q3 2025 to a low of $22.0 million in Q1 2022.
• The 5-year median for Total Liabilities is $45.8 million (2023), against an average of $44.3 million.
• Across the five-year window, Total Liabilities sank 31.7% in 2022 and surged 107.76% in 2023, its largest moves.
• Solid Biosciences' Total Liabilities stood at $48.6 million in 2022, then dropped by 20.85% to $38.5 million in 2023, then soared by 33.69% to $51.4 million in 2024, then advanced by 2.17% to $52.5 million in 2025, then dropped by 7.17% to $48.8 million in 2026.
• The last three Total Liabilities figures came in at $48.8 million (Q1 2026), $52.5 million (Q4 2025), and $56.0 million (Q3 2025), per Business Quant data.